Skip to main content

Table 3 Adverse events causally related to treatment (at least possible) reported in at least 2% in any subgroup of patients (sorted by percentages in the 'All patients' group).

From: Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?

Age

6-12 years

N = 583

13-18 years

N = 239

All patients

N = 822

Adverse event (AE)

[preferred term]

n

%

n

%

n

%

Patients with at least one AE*

149

25.56

46

19.25

195

23.72

Insomnia

48

8.23

11

4.60

59

7.18

Anorexia

31

5.32

4

1.67

35

4.26

Muscle contractions involuntary

29

4.97

5

2.09

34

4.14

Medicine ineffective

13

2.23

5

2.09

18

2.19

Nervousness

13

2.23

4

1.67

17

2.07

Headache

10

1.72

5

2.09

15

1.82

Concentration impaired

7

1.20

7

2.93

14

1.70

Aggressive reaction

8

1.37

5

2.09

13

1.58

Abdominal pain

12

2.06

0

0.00

12

1.46

Weight decrease

4

0.69

6

2.51

10

1.22

  1. * Chi2- Test: p = 0.066; some patients had more than one AE.